# Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)

> **NCT04820673** · — · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 300 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Sarecycline

## Key facts

- **NCT ID:** NCT04820673
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-09
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-05-04
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04820673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04820673, "Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04820673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*